Unichem Labs gets USFDA nod to market generic version of Otezla; stock ends 5 per cent higher

Unichem Laboratories Ltd, an international, integrated, speciality pharmaceutical company informed the exchanges on Friday that it has received ANDA approval for its Apremilast tablets in the strengths of 10 mg, 20 mg & 30 mg by United States Food & Drug Administration (USFDA).  

The abovementioned drug is the generic version of Amgen’s Otezla (Apremilast) tablets, 10 mg, 20 mg, and 30 mg. It is used for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.  

Unichem Laboratories is engaged in the manufacturing and marketing of a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.  

Reacting to the news, the stock of Unichem Laboratories closed at Rs 320.70 per share on Friday, up by 4.94 per cent or 15.10 per share, against a 0.85 per cent decline in the benchmark index. The 52-week high is recorded at Rs 332.40 while its 52-week low is Rs 75.10 on BSE.